India-based Lupin has entered into an agreement with ItalFarmaco, an Italian pharmaceutical company, to market the cardiovascular critical-care product Lupenox (Enoxaparin sodium injection) in the Indian market.
"Lupin has always made quality products affordable to Indian patients," said Satki Chakraborty, president for Indian-region formulations at Lupin. "Our tie-up with ItalFarmaco is yet another effort in this direction. In life critical situations, quality is of paramount importance."
